{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T07:56:26Z","timestamp":1793692586785,"version":"4.5.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T00:00:00Z","timestamp":1750550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK134321"],"award-info":[{"award-number":["U01DK134321"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis. Hyperbaric oxygen therapy involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. It reduces systemic and local inflammation and up-regulates hypoxia response pathways, making it an attractive therapeutic option. In this trial we aim to confirm the treatment benefits of hyperbaric oxygen therapy for hospitalized ulcerative colitis patients and assess the long-term durability of treatment effect.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This prospective, double-masked, multicenter, 1:1 randomized, sham-controlled trial will enroll 126 participants with known or newly diagnosed ulcerative colitis hospitalized for an acute moderate to severe flare. Participants will be randomized to either hyperbaric oxygen therapy with steroids or sham air with steroids. The trial will involve a 5-day intervention period followed by a 12-month observational period with a 90-day standard of care visit and 12-month telephone visit. The primary outcome measure is clinical response defined as complete resolution of rectal bleeding and improvement in stool frequency, without need for in-hospital biologics, small molecules, or colectomy by study day 5. Secondary endpoints include additional key patient-reported outcomes and histo-endoscopic measures of disease activity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Novel and effective treatments are needed for this population to optimize disease outcomes while minimizing treatment-related risks. Demonstrating the ability of hyperbaric oxygen therapy to improve clinical response to steroids and avoid in-hospital rescue therapy has the potential to change the management of hospitalized ulcerative colitis flares.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ClinicalTrials.gov NCT05987852. Registered on August 14, 2023.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-08932-5","type":"journal-article","created":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T05:40:50Z","timestamp":1750570850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Hyperbaric oxygen therapy for ulcerative colitis patients hospitalized for moderate to severe flares (HBOT-UC): study protocol for a multi-center, randomized, double-blind, sham-controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Lauren B.","family":"Bonner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Sadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Lindholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Scholtens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parambir S.","family":"Dulai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the HBOT-UC Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran","family":"Kochhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana J.","family":"Lukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jay C.","family":"Buckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny S.","family":"Sauk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marvin","family":"Heyboer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey M.","family":"Dueker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udayakumar","family":"Navaneethan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana M.","family":"Damas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W.","family":"Dryden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne G.","family":"Tuskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk B.","family":"Russ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Beth","family":"Tull","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Pi\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libeth","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Rypstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Heffernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Toups","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Hassan","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Shields","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Tabaja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanth","family":"Adusumalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Gutium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Conlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Viglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie B.","family":"Wabich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Aswath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald H.","family":"Markovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Abed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Acevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Ajalat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan O.","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Ioannou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelina","family":"Meza-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreana","family":"Teran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niurka","family":"Colina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mijares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Scanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"AlhajHusain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany J","family":"Behar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,22]]},"reference":[{"key":"8932_CR1","doi-asserted-by":"publisher","unstructured":"Ma C, Smith MK, Guizzetti L, et al. Assessing national trends and disparities in ambulatory, emergency department, and inpatient visits for inflammatory bowel disease in the United States (2005\u20132016). Clin Gastroenterol Hepatol 2020; 18: 2500\u20132509.e2501. 20200125. https:\/\/doi.org\/10.1016\/j.cgh.2020.01.023.","DOI":"10.1016\/j.cgh.2020.01.023"},{"key":"8932_CR2","doi-asserted-by":"publisher","unstructured":"Fumery M, Singh S, Dulai PS, et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin Gastroenterol Hepatol 2018; 16: 343\u2013356.e343. 20170616. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.016.","DOI":"10.1016\/j.cgh.2017.06.016"},{"issue":"237\u2013243","key":"8932_CR3","doi-asserted-by":"publisher","first-page":"20170104","DOI":"10.1136\/gutjnl-2016-313060","volume":"67","author":"D Laharie","year":"2018","unstructured":"Laharie D, Bourreille A, Branche J, et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut. 2018;67(237\u2013243):20170104. https:\/\/doi.org\/10.1136\/gutjnl-2016-313060.","journal-title":"Gut"},{"key":"8932_CR4","doi-asserted-by":"publisher","unstructured":"Nguyen NH, Koola J, Dulai PS, et al. Rate of risk factors for and interventions to reduce hospital readmission in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2020; 18: 1939\u20131948.e1937. 20190827. https:\/\/doi.org\/10.1016\/j.cgh.2019.08.042.","DOI":"10.1016\/j.cgh.2019.08.042"},{"issue":"1709\u20131718","key":"8932_CR5","doi-asserted-by":"publisher","first-page":"20170704","DOI":"10.1038\/ajg.2017.180","volume":"112","author":"I Ord\u00e1s","year":"2017","unstructured":"Ord\u00e1s I, Dom\u00e8nech E, Ma\u00f1osa M, et al. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989\u20132013): A Nationwide Multicenter Study. Am J Gastroenterol. 2017;112(1709\u20131718):20170704. https:\/\/doi.org\/10.1038\/ajg.2017.180.","journal-title":"Am J Gastroenterol"},{"key":"8932_CR6","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/ibd\/izz055","volume":"25","author":"JL Opstelten","year":"2019","unstructured":"Opstelten JL, Vaartjes I, Bots ML, et al. Mortality After First Hospital Admission for Inflammatory Bowel Disease: A Nationwide Registry Linkage Study. Inflamm Bowel Dis. 2019;25:1692\u20139. https:\/\/doi.org\/10.1093\/ibd\/izz055.","journal-title":"Inflamm Bowel Dis"},{"key":"8932_CR7","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.cgh.2008.05.022","volume":"6","author":"J Allison","year":"2008","unstructured":"Allison J, Herrinton LJ, Liu L, et al. Natural history of severe ulcerative colitis in a community-based health plan. Clin Gastroenterol Hepatol. 2008;6:999\u20131003. https:\/\/doi.org\/10.1016\/j.cgh.2008.05.022.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"972\u2013980","key":"8932_CR8","doi-asserted-by":"publisher","first-page":"20110730","DOI":"10.1016\/j.cgh.2011.07.016","volume":"9","author":"S de Silva","year":"2011","unstructured":"de Silva S, Ma C, Proulx MC, et al. Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol. 2011;9(972\u2013980):20110730. https:\/\/doi.org\/10.1016\/j.cgh.2011.07.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"928\u2013937","key":"8932_CR9","doi-asserted-by":"publisher","first-page":"20150606","DOI":"10.1053\/j.gastro.2015.06.001","volume":"149","author":"S Singh","year":"2015","unstructured":"Singh S, Al-Darmaki A, Frolkis AD, et al. Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies. Gastroenterology. 2015;149(928\u2013937):20150606. https:\/\/doi.org\/10.1053\/j.gastro.2015.06.001.","journal-title":"Gastroenterology"},{"issue":"1909\u20131915","key":"8932_CR10","doi-asserted-by":"publisher","first-page":"20121010","DOI":"10.1016\/s0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(1909\u20131915):20121010. https:\/\/doi.org\/10.1016\/s0140-6736(12)61084-8.","journal-title":"Lancet"},{"issue":"477\u2013491","key":"8932_CR11","doi-asserted-by":"publisher","first-page":"20160209","DOI":"10.1038\/ajg.2016.7","volume":"111","author":"N Narula","year":"2016","unstructured":"Narula N, Marshall JK, Colombel JF, et al. Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids. Am J Gastroenterol. 2016;111(477\u2013491):20160209. https:\/\/doi.org\/10.1038\/ajg.2016.7.","journal-title":"Am J Gastroenterol"},{"issue":"525\u2013541","key":"8932_CR12","doi-asserted-by":"publisher","first-page":"20140613","DOI":"10.1016\/j.gtc.2014.05.010","volume":"43","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Siegel CA. The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease. Gastroenterol Clin North Am. 2014;43(525\u2013541):20140613. https:\/\/doi.org\/10.1016\/j.gtc.2014.05.010.","journal-title":"Gastroenterol Clin North Am"},{"issue":"1843\u20131853","key":"8932_CR13","doi-asserted-by":"publisher","first-page":"20140626","DOI":"10.1136\/gutjnl-2014-307126","volume":"63","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Siegel CA, Colombel JF, et al. Systematic review: Monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD. Gut. 2014;63(1843\u20131853):20140626. https:\/\/doi.org\/10.1136\/gutjnl-2014-307126.","journal-title":"Gut"},{"key":"8932_CR14","doi-asserted-by":"publisher","unstructured":"Abraham C, Dulai PS, Vermeire S, et al. Lessons Learned From Trials Targeting Cytokine Pathways in\u00a0Patients With Inflammatory Bowel Diseases. Gastroenterology 2017; 152: 374\u2013388.e374. 20161022. https:\/\/doi.org\/10.1053\/j.gastro.2016.10.018.","DOI":"10.1053\/j.gastro.2016.10.018"},{"key":"8932_CR15","doi-asserted-by":"publisher","unstructured":"Albenberg L, Esipova TV, Judge CP, et al. Correlation between intraluminal oxygen gradient and radial partitioning of intestinal microbiota. Gastroenterology 2014; 147: 1055\u20131063.e1058. 20140718. https:\/\/doi.org\/10.1053\/j.gastro.2014.07.020.","DOI":"10.1053\/j.gastro.2014.07.020"},{"issue":"364\u2013368","key":"8932_CR16","doi-asserted-by":"publisher","first-page":"20160111","DOI":"10.1097\/jim.0000000000000218","volume":"64","author":"SP Colgan","year":"2016","unstructured":"Colgan SP. Targeting hypoxia in inflammatory bowel disease. J Investig Med. 2016;64(364\u2013368):20160111. https:\/\/doi.org\/10.1097\/jim.0000000000000218.","journal-title":"J Investig Med"},{"issue":"246\u2013255","key":"8932_CR17","doi-asserted-by":"publisher","first-page":"20150521","DOI":"10.1016\/j.gie.2015.03.1974","volume":"82","author":"PS Dulai","year":"2015","unstructured":"Dulai PS, Levesque BG, Feagan BG, et al. Assessment of mucosal healing in inflammatory bowel disease: review. Gastrointest Endosc. 2015;82(246\u2013255):20150521. https:\/\/doi.org\/10.1016\/j.gie.2015.03.1974.","journal-title":"Gastrointest Endosc"},{"issue":"130\u2013140","key":"8932_CR18","doi-asserted-by":"publisher","first-page":"20121102","DOI":"10.1016\/j.freeradbiomed.2012.10.554","volume":"55","author":"MG Espey","year":"2013","unstructured":"Espey MG. Role of oxygen gradients in shaping redox relationships between the human intestine and its microbiota. Free Radic Biol Med. 2013;55(130\u2013140):20121102. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2012.10.554.","journal-title":"Free Radic Biol Med"},{"key":"8932_CR19","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1053\/j.gastro.2011.01.056","volume":"140","author":"LE Glover","year":"2011","unstructured":"Glover LE, Colgan SP. Hypoxia and metabolic factors that influence inflammatory bowel disease pathogenesis. Gastroenterology. 2011;140:1748\u201355. https:\/\/doi.org\/10.1053\/j.gastro.2011.01.056.","journal-title":"Gastroenterology"},{"issue":"e013477","key":"8932_CR20","doi-asserted-by":"publisher","first-page":"20170105","DOI":"10.1136\/bmjopen-2016-013477","volume":"7","author":"S Vavricka","year":"2017","unstructured":"Vavricka S, Ruiz PA, Scharl S, et al. Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. BMJ Open. 2017;7(e013477):20170105. https:\/\/doi.org\/10.1136\/bmjopen-2016-013477.","journal-title":"BMJ Open"},{"issue":"612\u2013626","key":"8932_CR21","doi-asserted-by":"publisher","first-page":"20121011","DOI":"10.1016\/j.molcel.2012.08.033","volume":"48","author":"DR Donohoe","year":"2012","unstructured":"Donohoe DR, Collins LB, Wali A, et al. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol Cell. 2012;48(612\u2013626):20121011. https:\/\/doi.org\/10.1016\/j.molcel.2012.08.033.","journal-title":"Mol Cell"},{"issue":"662\u2013671","key":"8932_CR22","doi-asserted-by":"publisher","first-page":"20150409","DOI":"10.1016\/j.chom.2015.03.005","volume":"17","author":"CJ Kelly","year":"2015","unstructured":"Kelly CJ, Zheng L, Campbell EL, et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe. 2015;17(662\u2013671):20150409. https:\/\/doi.org\/10.1016\/j.chom.2015.03.005.","journal-title":"Cell Host Microbe"},{"issue":"250\u2013253","key":"8932_CR23","doi-asserted-by":"publisher","first-page":"20140123","DOI":"10.4161\/gmic.27917","volume":"5","author":"AS Neish","year":"2014","unstructured":"Neish AS, Jones RM. Redox signaling mediates symbiosis between the gut microbiota and the intestine. Gut Microbes. 2014;5(250\u2013253):20140123. https:\/\/doi.org\/10.4161\/gmic.27917.","journal-title":"Gut Microbes"},{"issue":"Suppl 1","key":"8932_CR24","doi-asserted-by":"publisher","first-page":"131s","DOI":"10.1097\/PRS.0b013e3181fbe2bf","volume":"127","author":"SR Thom","year":"2011","unstructured":"Thom SR. Hyperbaric oxygen: its mechanisms and efficacy. Plast Reconstr Surg. 2011;127(Suppl 1):131s\u201341s. https:\/\/doi.org\/10.1097\/PRS.0b013e3181fbe2bf.","journal-title":"Plast Reconstr Surg"},{"issue":"281\u2013287","key":"8932_CR25","doi-asserted-by":"publisher","first-page":"20100406","DOI":"10.1038\/nrgastro.2010.39","volume":"7","author":"SP Colgan","year":"2010","unstructured":"Colgan SP, Taylor CT. Hypoxia: an alarm signal during intestinal inflammation. Nat Rev Gastroenterol Hepatol. 2010;7(281\u2013287):20100406. https:\/\/doi.org\/10.1038\/nrgastro.2010.39.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1266\u20131275","key":"8932_CR26","doi-asserted-by":"publisher","first-page":"20140416","DOI":"10.1111\/apt.12753","volume":"39","author":"PS Dulai","year":"2014","unstructured":"Dulai PS, Gleeson MW, Taylor D, et al. Systematic review: The safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(1266\u20131275):20140416. https:\/\/doi.org\/10.1111\/apt.12753.","journal-title":"Aliment Pharmacol Ther"},{"issue":"86\u201392","key":"8932_CR27","doi-asserted-by":"publisher","first-page":"20160928","DOI":"10.1016\/j.freeradbiomed.2016.09.027","volume":"105","author":"C Chun","year":"2017","unstructured":"Chun C, Zheng L, Colgan SP. Tissue metabolism and host-microbial interactions in the intestinal mucosa. Free Radic Biol Med. 2017;105(86\u201392):20160928. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2016.09.027.","journal-title":"Free Radic Biol Med"},{"issue":"1516\u20131523","key":"8932_CR28","doi-asserted-by":"publisher","first-page":"20180216","DOI":"10.1038\/s41395-018-0005-z","volume":"113","author":"PS Dulai","year":"2018","unstructured":"Dulai PS, Buckey JC Jr, Raffals LE, et al. Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial. Am J Gastroenterol. 2018;113(1516\u20131523):20180216. https:\/\/doi.org\/10.1038\/s41395-018-0005-z.","journal-title":"Am J Gastroenterol"},{"issue":"955\u2013963","key":"8932_CR29","doi-asserted-by":"publisher","first-page":"20200803","DOI":"10.1111\/apt.15984","volume":"52","author":"PS Dulai","year":"2020","unstructured":"Dulai PS, Raffals LE, Hudesman D, et al. A phase 2B randomised trial of hyperbaric oxygen therapy for ulcerative colitis patients hospitalised for moderate to severe flares. Aliment Pharmacol Ther. 2020;52(955\u2013963):20200803. https:\/\/doi.org\/10.1111\/apt.15984.","journal-title":"Aliment Pharmacol Ther"},{"issue":"462\u2013476","key":"8932_CR30","doi-asserted-by":"publisher","first-page":"20180604","DOI":"10.1177\/1740774518776952","volume":"15","author":"CA Lansdorp","year":"2018","unstructured":"Lansdorp CA, van Hulst RA. Double-blind trials in hyperbaric medicine: A narrative review on past experiences and considerations in designing sham hyperbaric treatment. Clin Trials. 2018;15(462\u2013476):20180604. https:\/\/doi.org\/10.1177\/1740774518776952.","journal-title":"Clin Trials"},{"key":"8932_CR31","first-page":"345","volume":"40","author":"P Witucki","year":"2013","unstructured":"Witucki P, Duchnick J, Neuman T, et al. Incidence of DCS and oxygen toxicity in chamber attendants: a 28-year experience. Undersea Hyperb Med. 2013;40:345\u201350.","journal-title":"Undersea Hyperb Med"},{"issue":"1450\u20131461","key":"8932_CR32","doi-asserted-by":"publisher","first-page":"20200113","DOI":"10.1053\/j.gastro.2020.01.006","volume":"158","author":"JD Feuerstein","year":"2020","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology. 2020;158(1450\u20131461):20200113. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006.","journal-title":"Gastroenterology"},{"key":"8932_CR33","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152.","journal-title":"Am J Gastroenterol"},{"key":"8932_CR34","doi-asserted-by":"publisher","unstructured":"Pola S, Patel D, Ramamoorthy S, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 2012; 10: 1315\u20131325.e1314. 20120724. https:\/\/doi.org\/10.1016\/j.cgh.2012.07.006.","DOI":"10.1016\/j.cgh.2012.07.006"},{"issue":"65\u201372","key":"8932_CR35","doi-asserted-by":"publisher","first-page":"20171124","DOI":"10.1177\/2040622317742095","volume":"9","author":"PS Dulai","year":"2018","unstructured":"Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9(65\u201372):20171124. https:\/\/doi.org\/10.1177\/2040622317742095.","journal-title":"Ther Adv Chronic Dis"},{"key":"8932_CR36","doi-asserted-by":"publisher","unstructured":"Dulai PS, Bonner LB, Sadler C, et al. Clinical trial design considerations for hospitalised patients with ulcerative colitis flares and application to study hyperbaric oxygen therapy in the NIDDK HBOT-UC Consortium. Aliment Pharmacol Ther 2024 20241015. https:\/\/doi.org\/10.1111\/apt.18326.","DOI":"10.1111\/apt.18326"},{"key":"8932_CR37","doi-asserted-by":"publisher","unstructured":"Le Berre C and Peyrin-Biroulet L. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021; 160: 1452\u20131460.e1421. 20210106. https:\/\/doi.org\/10.1053\/j.gastro.2020.10.065.","DOI":"10.1053\/j.gastro.2020.10.065"},{"key":"8932_CR38","unstructured":"Food and Drug Administration. Ulcerative colitis: clinical trial endpoints guidance for industry, 2016.\u00a0https:\/\/www.fda.gov\/files\/drugs\/published\/Ulcerative-Colitis--Clinical-Trial-Endpoints-Guidance-for-Industry.pdf."},{"key":"8932_CR39","doi-asserted-by":"publisher","unstructured":"Dulai PS, Peyrin-Biroulet L, Danese S, et al. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology 2019; 157: 1032\u20131043.e1031. 20190619. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.018.","DOI":"10.1053\/j.gastro.2019.06.018"},{"issue":"1324\u20131338","key":"8932_CR40","doi-asserted-by":"publisher","first-page":"20150825","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(1324\u20131338):20150825. https:\/\/doi.org\/10.1038\/ajg.2015.233.","journal-title":"Am J Gastroenterol"},{"issue":"1570\u20131583","key":"8932_CR41","doi-asserted-by":"publisher","first-page":"20210219","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160(1570\u20131583):20210219. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031.","journal-title":"Gastroenterology"},{"issue":"987\u2013995","key":"8932_CR42","doi-asserted-by":"publisher","first-page":"20130725","DOI":"10.1053\/j.gastro.2013.07.024","volume":"145","author":"SP Travis","year":"2013","unstructured":"Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(987\u2013995):20130725. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.024.","journal-title":"Gastroenterology"},{"key":"8932_CR43","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ibd.20520","volume":"14","author":"JD Lewis","year":"2008","unstructured":"Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660\u20136. https:\/\/doi.org\/10.1002\/ibd.20520.","journal-title":"Inflamm Bowel Dis"},{"issue":"31","key":"8932_CR44","doi-asserted-by":"publisher","first-page":"20220401","DOI":"10.1186\/s41687-022-00439-w","volume":"6","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Irving PM, Panaccione R, et al. Incorporating patient experience into drug development for ulcerative colitis: development of the Urgency Numeric Rating Scale, a patient-reported outcome measure to assess bowel urgency in adults. J Patient Rep Outcomes. 2022;6(31):20220401. https:\/\/doi.org\/10.1186\/s41687-022-00439-w.","journal-title":"J Patient Rep Outcomes"},{"key":"8932_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/gut.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29\u201332. https:\/\/doi.org\/10.1136\/gut.43.1.29.","journal-title":"Gut"},{"key":"8932_CR46","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010.","journal-title":"J Biomed Inform"},{"key":"8932_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208.","journal-title":"J Biomed Inform"},{"key":"8932_CR48","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1002\/sim.4102","volume":"30","author":"CR Mehta","year":"2011","unstructured":"Mehta CR, Pocock SJ. Adaptive increase in sample size when interim results are promising: A practical guide with examples. Stat Med. 2011;30:3267\u201384. https:\/\/doi.org\/10.1002\/sim.4102.","journal-title":"Stat Med"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08932-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08932-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08932-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,22]],"date-time":"2025-06-22T05:40:51Z","timestamp":1750570851000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08932-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,22]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8932"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08932-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,22]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by Advarra, serving as the single IRB. Written informed consent to participate will be obtained from all participants, or their legally authorized representatives if applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable. Informed consent materials will be made available by the corresponding author upon request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors have none to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"220"}}